HealthTree

Showing 153 trials matching your filters.

Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and M...

This phase II trial studies the effect of venetoclax together with busulfan, cladribine, and fludarabine in treating patients with high-risk acute myeloid leukemia or myelodysplastic syndrome who are undergoing stem cell transplant. Chemotherapy drug...

DRUG: Busulfan

DRUG: Cladribine

DRUG: Fludarabine Phosphate

PROCEDURE: Hematopoietic Cell Transplantation

DRUG: Thiotepa

DRUG: Venetoclax

Allo HSCT Using RIC and PTCy for Hematological Diseases

This is a Phase II study following subjects proceeding with our Institutional non-myeloablative cyclophosphamide/ fludarabine/total body irradiation (TBI) preparative regimen followed by a related, unrelated, or partially matched family donor stem ce...

BIOLOGICAL: Peripheral Blood Stem Cell Transplant

DRUG: Allopurinol 300 MG

DRUG: Fludarabine

DRUG: Cyclophosphamide

BIOLOGICAL: Bone Marrow Cell Transplant

RADIATION: Total Body Irradiation

DRUG: Sirolimus Pill

DRUG: Mycophenolate Mofetil

Study of DISC-0974 in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia

This phase 1b/2a open-label study will assess the safety, tolerability, pharmacokinetics and pharmacodynamics of DISC-0974 as well as categorize the effects on anemia response in subjects with myelofibrosis or myelodysplastic syndrome and anemia.

DRUG: DISC-0974

A Study of Oral TP-3654 in Patients With Myelofibrosis

This study is a Phase 1/2, multicenter, dose-escalation, open-label trial to assess safety, tolerability, pharmacokinetics and pharmacodynamics of TP-3654 in patients with intermediate or high-risk primary or secondary MF.

DRUG: TP-3654

DRUG: Ruxolitinib

DRUG: Momelotinib

Intra-patient Dose Escalation Study to Investigate Safety and Feasibility of Vactosertib in Treating...

This study assesses the potential of using a TGFβ receptor inhibitor for the treatment of anemic patients with myeloproliferative neoplasms. TGFβ signaling is known to be abnormally high in patients with myeloproliferative neoplasms and it is thought...

DRUG: Vactosertib

Fedratinib in Myelodysplastic /Myeloproliferative Neoplasms (MDS/MPNs) and Chronic Neutrophilic Leuk...

The purpose of the study is to evaluate the effectiveness, safety, and tolerability of a study drug called fedratinib in participants with myelodysplastic/myeloproliferative neoplasms (MDS/MPNs) and chronic neutrophilic leukemia (CNL).

DRUG: Fedratinib Pill

Pacritinib w/ Talazoparib in Pts w/ Myeloproliferative Neoplasms Unresponsive to JAK2 Inhibition

This is a prospective phase I dose-escalation study, with the primary objective to access the MTD and find the RP2D of talazoparib, given in combination with standard of care dosing of pacritinib.

DRUG: Talazoparib

DRUG: pacritinib

A Study to Evaluate the Safety, Tolerability of INCB160058 in Participants With Myeloproliferative N...

This study is being conducted to assess the Safety, Tolerability, and Pharmacokinetics of INCB160058 in Participants With Myeloproliferative Neoplasms.

DRUG: INCB160058

A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Pa...

This phase I trial tests the safety, side effects, and best dose of imetelstat in combination with fludarabine and cytarabine in treating patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) or juvenile myelomonocytic leukemia (...

PROCEDURE: Biospecimen Collection

PROCEDURE: Bone Marrow Aspiration

PROCEDURE: Bone Marrow Biopsy

DRUG: Cytarabine

PROCEDURE: Echocardiography

DRUG: Fludarabine

DRUG: Hydrocortisone Sodium Succinate

BIOLOGICAL: Imetelstat

DRUG: Leucovorin Calcium

PROCEDURE: Lumbar Puncture

DRUG: Methotrexate

Reduced-Intensity Conditioning for the Prevention of Treatment-Related Mortality in Patients Who Und...

This phase II clinical trial evaluates whether a modified modality of conditioning reduces treatment-related mortality (TRM) in patients who undergo a hematopoietic stem cell transplant (HSCT) for a hematological malignancy. HSCT is a curative therap...

PROCEDURE: Hematopoietic Cell Transplantation

DRUG: Mycophenolate Mofetil

DRUG: Tacrolimus

DRUG: Cyclophosphamide

RADIATION: Total-Body Irradiation

PROCEDURE: Donor Lymphocyte Infusion

DRUG: Fludarabine

DRUG: Melphalan

Onvansertib for the Treatment of Recurrent or Refractory Chronic Myelomonocytic Leukemia

This phase I trial evaluates the safety, effectiveness, and best dose of onvansertib for the treatment of patients with chronic myelomonocytic leukemia that has come back (recurrent) or that does not respond to treatment (refractory). Onvansertib is ...

PROCEDURE: Biospecimen Collection

PROCEDURE: Bone Marrow Aspiration and Biopsy

DRUG: Onvansertib

PROCEDURE: Ultrasound Imaging

HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclopho...

This is a prospective, multi-center, Phase II study of hematopoietic cell transplantation (HCT) using human leukocyte antigen (HLA)-mismatched unrelated donors (MMUD) for peripheral blood stem cell transplant in adults and bone marrow stem cell trans...

DRUG: Busulfan

DRUG: Fludarabine

RADIATION: Total-body irradiation

DRUG: Cyclophosphamide

DRUG: Melphalan

PROCEDURE: PBSC Hematopoietic Stem Cell Transplantation (HSCT)

PROCEDURE: Bone Marrow Hematopoietic Stem Cell Transplantation

DRUG: Post-transplant Cyclophosphamide

DRUG: Mesna

DRUG: Tacrolimus

DRUG: Mycophenolate Mofetil

OTHER: Patient-Reported Outcomes

Mutant CALR-peptide Based Vaccine in Patients With Mutated CALR Myeloproliferative Neoplasm

The primary objective of this study is to assess the safety and tolerability of administrating mutated-CALR peptide Vaccine to patients with MPN. The researchers plan to enroll 10 patients over a 12 month period. Maximum length of participation in 80...

DRUG: Peptide-based vaccine

DRUG: Poly ICLC

Luspatercept for Anemia in Lower Risk MDS or Non-proliferative MDS/MPN Neoplasms

The purpose of the study is to see if participants with anemia due to their type of MDS or MDS/MPN will experience a more decreased need for regular blood transfusions if they take luspatercept plus best supportive care, and what effect, good and/or ...

DRUG: Luspatercept

Ruxolitinib in Thrombocythemia and Polycythemia Vera

This research is being done to see if the drug ruxolitinib is effective in reducing the symptoms caused by low-risk essential thrombocythemia (ET) and polycythemia vera (PV). - This research study involves the study drug Ruxolitinib.

DRUG: Ruxolitinib

Vorinostat Dose-escalation After Allogeneic Hematopoietic Cell Transplantation

The objective of this study is to evaluate the maximum tolerated (MTD) of vorinostat used in combination with low-dose azacitidine after allogeneic hematopoietic cell transplantation (alloHCT) for prevention of relapse of childhood myeloid malignanci...

DRUG: Vorinostat

DRUG: Azacitidine Injection

Study of Olverembatinib (HQP1351) in Patients With CP-CML

A Global Multicenter, Open Label, Randomized, Phase 3 Registrational Study of Olverembatinib (HQP1351) in Patients with Chronic Phase Chronic Myeloid Leukemia (POLARIS-2)

DRUG: olverembatinib

DRUG: Bosutinib

Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase M...

This phase II trial studies how well decitabine with ruxolitinib, fedratinib, or pacritinib works before hematopoietic stem cell transplant in treating patients with accelerated/blast phase myeloproliferative neoplasms (tumors). Drugs used in chemoth...

DRUG: Decitabine

DRUG: Ruxolitinib

DRUG: Fedratinib

OTHER: Questionnaire Administration

DRUG: Pacritinib

Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome

This phase II trial studies the side effects and how well azacitidine and enasidenib work in treating patients with IDH2-mutant myelodysplastic syndrome. Azacitidine and enasidenib may stop the growth of cancer cells by blocking some of the enzymes n...

DRUG: Azacitidine

DRUG: Enasidenib

OTHER: Quality-of-Life Assessment

Open Label Phase 2 Study of Tasquinimod in Patients With Primary Myelofibrosis (PMF), Post-Polycythe...

To learn if tasquinimod either alone or in combination with ruxolitinib can help to control PMF, post-PV MF, or post-ET MF.

DRUG: Ruxolitinib

DRUG: Tasquinimod

Study of TL-895 Combined With Ruxolitinib in JAKi Treatment-Naïve MF Subjects and Subjects With MF W...

This study evaluates TL-895, a potent, orally-available and highly selective irreversible tyrosine kinase inhibitor for the treatment of Myelofibrosis. Participants must have MF (PMF, Post PV MF, or Post ET MF) who are JAKi treatment-naïve or those w...

DRUG: TL-895

DRUG: Ruxolitinib

A Study of APG-115 Alone or Combined With Azacitidine in Patients With AML, CMML, or MDS

This is a two Part study in patients with relapsed/refractory acute myeloid leukemia (AML), chronic myelomonocytic leukemia (CMML), or high risk myelodysplastic syndrome (MDS) that will initially evaluate the safety and tolerability of APG-115 as a s...

DRUG: APG-115

DRUG: 5-azacitidine

A Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of P1101 in Adults ...

A Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of Ropeginterferon alfa-2b-njft (P1101) in Adult Patients with Essential Thrombocythemia

DRUG: Ropeginterferon alfa-2b-njft (P1101)

Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutate...

This phase I/II trial studies the side effects and best dose of gilteritinib and to see how well it works in combination with azacitidine and venetoclax in treating patients with FLT3-mutation positive acute myeloid leukemia, chronic myelomonocytic l...

DRUG: Azacitidine

DRUG: Gilteritinib

DRUG: Venetoclax

Asciminib Monotherapy, With Dose Escalation, for 2nd and 1st Line Chronic Myelogenous Leukemia

This will be a multicenter Phase II open-label study of asciminib in CML-CP patients who have been previously treated with one prior ATP- binding site TKI with discontinuation due to treatment failure, warning or intolerance. (2L patient cohort). In ...

DRUG: asciminib

Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatmen...

This phase II trial studies how well a donor stem cell transplant, treosulfan, fludarabine, and total-body irradiation work in treating patients with blood cancers (hematological malignancies). Giving chemotherapy and total-body irradiation before a ...

PROCEDURE: Allogeneic Hematopoietic Stem Cell Transplantation

DRUG: Cyclophosphamide

DRUG: Cyclosporine

BIOLOGICAL: Filgrastim

DRUG: Fludarabine

DRUG: Mycophenolate Mofetil

DRUG: Mycophenolate Sodium

RADIATION: Total-Body Irradiation

DRUG: Treosulfan

PROCEDURE: Bone Marrow Aspiration

PROCEDURE: Bone Marrow Biopsy

PROCEDURE: Echocardiography

PROCEDURE: Biospecimen Collection

PROCEDURE: Computed Tomography

PROCEDURE: Positron Emission Tomography

(Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indo...

This is a multi-part, randomized, double-blind, placebo-controlled Phase 2 clinical study comparing the safety and efficacy of bezuclastinib (CGT9486) plus best supportive care (BSC) with placebo plus BSC in patients with nonadvanced systemic mastocy...

DRUG: Bezuclastinib Tablets (Formulation A)

DRUG: Bezuclastinib Tablets (Formulation B)

DRUG: Placebo Tablets

A Study to Assess Efficacy, Safety, and Tolerability of P1101 in Adult Patients With PV

A Study to Assess Efficacy, Safety, and Tolerability of P1101 in Adult Patients with PV

DRUG: P1101 (Ropeginterferon alfa-2b-njft)

DRUG: Ropeginterferon alfa-2b-njft (P1101)

Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced My...

The purpose of this study is to evaluate the safety, tolerability, and preliminary efficacy of INCB057643 as monotherapy or combination with ruxolitinib for participants with myelofibrosis (MF) and other myeloid neoplasms.

DRUG: INCB057643

DRUG: Ruxolitinib

A Phase 1a/1b Study of ELVN-001 for the Treatment Chronic Myeloid Leukemia

The purpose of this study is to evaluate the safety, tolerability and determine the recommended dose for further clinical evaluation of ELVN-001 in patients with chronic myeloid leukemia with and without T315I mutations in patients who are relapsed, ...

DRUG: ELVN-001

Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia ...

This phase II trial studies how well enasidenib and azacitidine work in treating patients with IDH2 gene mutation and acute myeloid leukemia that has come back (recurrent) or does not respond to treatment (refractory). Enasidenib and azacitidine may ...

DRUG: Azacitidine

DRUG: Enasidenib Mesylate

Cord Blood Transplant in Adults With Blood Cancers

Cord blood transplants (CBT) are a standard treatment for adults with blood cancers. MSK has developed a standard ("optimized") practice for cord blood transplant (CBT). This optimized practice includes how patients are evaluated for transplant, the ...

DRUG: Conditioning Chemotherapy

BIOLOGICAL: Cord blood graft

Ivosidenib and Combination Chemotherapy for the Treatment of IDH1 Mutant Relapsed or Refractory Acut...

This phase I trial studies the side effects and best dose of ivosidenib when given together with combination chemotherapy for the treatment of 1DH1 mutant acute myeloid leukemia that has come back (relapsed) or does not respond to treatment (refracto...

DRUG: Cytarabine

BIOLOGICAL: Filgrastim

DRUG: Fludarabine

DRUG: Fludarabine Phosphate

DRUG: Ivosidenib

Itacitinib With High-dose Posttransplantation Cyclophosphamide in Older Patients

This research is being done to learn whether drug called itacitinib, which is a novel inflammation- and immune-lowering drug (immunosuppressant), can be given before and after non-myeloablative peripheral blood stem cell transplantation (PBSCT; also ...

DRUG: Itacitinib

Venetoclax and Azacitidine for the Treatment of High-Risk Recurrent or Refractory Myelodysplastic Sy...

This phase I/II trial studies the side effects and best dose of venetoclax when given together with azacitidine in treating patients with high-risk myelodysplastic syndrome that has come back (recurrent) or does not respond to treatment (refractory)....

DRUG: Azacitidine

DRUG: Venetoclax

TGRX-678 US Phase I for Subjects With Refractory or Advanced Chronic Myelogenous Leukemia

The purpose of this single-arm, open-label, dose escalation + cohort expansion study is to evaluate the safety, tolerability, pharmacokinetic and preliminary efficacy of TGRX-678 in Chronic Myelogenous Leukemia patients who had failure with or are in...

DRUG: TGRX-678

HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Tra...

The goal of this clinical trial is to determine the effectiveness of Reduced Dose Post-Transplant Cyclophosphamide (PTCy) in patients with hematologic malignancies after receiving an HLA-Mismatched Unrelated Donor (MMUD) . The main question\[s\] it a...

DRUG: Busulfan

DRUG: Fludarabine

PROCEDURE: PBSC Hematopoietic Stem Cell Transplantation (HSCT)

DRUG: Post-Transplant Cyclophosphamide

DRUG: Mesna

DRUG: Tacrolimus

DRUG: Mycophenolate Mofetil

OTHER: Patient Reported Outcomes

DRUG: Melphalan

RADIATION: Total-body irradiation

DRUG: Cyclophosphamide

Avapritinib With Decitabine in Patients With SM-AHN

Systemic mastocytosis with an associated hematologic neoplasm (SM-AHN) is a challenging disease to treat. Targeted KIT inhibitors have been approved for this indication based on their ability to control the mastocytosis portion of the disease, but pa...

DRUG: Avapritinib

DRUG: Decitabine

COMBINATION_PRODUCT: Decitabine/Cedazuridine

(HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent S...

This is a randomized, double-blind, placebo-controlled, Phase 2/3 study comparing the efficacy and safety of elenestinib (BLU-263) + best supportive care (BSC) with placebo + BSC in patients with indolent systemic mastocytosis (ISM) whose symptoms ar...

DRUG: Elenestinib

DRUG: Placebo

Cytokine-Treated Veto Cells in Treating Patients With Hematologic Malignancies Following Stem Cell T...

This phase I/II trial studies how well cytokine-treated veto cells work in treating patients with hematologic malignancies following stem cell transplant. Giving chemotherapy and total-body irradiation before a stem cell transplant helps stop the gro...

BIOLOGICAL: Anti-Thymocyte Globulin

DRUG: Cyclophosphamide

BIOLOGICAL: Cytokine-treated Veto Cells

DRUG: Fludarabine

PROCEDURE: Peripheral Blood Stem Cell Transplantation

RADIATION: Total-Body Irradiation

Provision of TCRγδ T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depl...

This study seeks to examine treatment therapy that will reduced regimen-related toxicity and relapse while promoting rapid immune reconstitution with limited serious graft-versus-host-disease (GVHD) and also improve disease-free survival and quality ...

DRUG: Anti-thymocyte globulin (rabbit)

DRUG: Blinatumomab

DRUG: Cyclophosphamide

DRUG: Fludarabine

DRUG: G-CSF

DRUG: Melphalan

DRUG: Mesna

DRUG: Rituximab

DRUG: Tacrolimus

DRUG: Thiotepa

BIOLOGICAL: HPC,A Infusion

DEVICE: CliniMACS

DRUG: Sirolimus

Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft

Reduced intensity conditioning (RIC) has emerged and been increasingly adopted as a modality to allow preparative conditioning pre transplant to be tolerated by older adults or those patients that are otherwise unfit for myeloablative conditioning. I...

DRUG: Purified regulatory T-cells (Treg) plus CD34+ HSPC

DRUG: Fludarabine

DRUG: Melphalan

DEVICE: CliniMACS CD34 Reagent System

DRUG: Tacrolimus

DRUG: Cyclophosphamide

DRUG: Plerixafor

DRUG: Filgrastim granulocyte colony-stimulating factor (G-CSF) or equivalent

DRUG: Thiotepa

DRUG: Mycophenolate Mofetil (MMF)

DRUG: Ruxolitinib

A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or Hi...

The purpose of the study is to evaluate the overall survival of participants treated with imetelstat compared to best available therapy with intermediate-2 or high-risk Myelofibrosis (MF) who are relapsed/refractory to Janus Kinase (JAK)-Inhibitor tr...

DRUG: Imetelstat

DRUG: Best Available Therapy (BAT)

Ruxolitinib Phosphate and Azacytidine in Treating Patients With Myelofibrosis or Myelodysplastic Syn...

This phase II trial studies how well ruxolitinib phosphate and azacytidine work in treating patients with myelofibrosis or myelodysplastic syndrome/myeloproliferative neoplasm. Ruxolitinib phosphate may stop the growth of cancer cells by blocking som...

DRUG: Azacitidine

OTHER: Laboratory Biomarker Analysis

DRUG: Ruxolitinib Phosphate

KRT-232 in Combination With TL-895 for the Treatment of R/R MF and KRT-232 for the Treatment of JAKi...

This study evaluates KRT-232 in Combination With TL-895 for the Treatment of Relapsed or Refractory Myelofibrosis and KRT-232 for the Treatment of JAK Inhibitor Intolerant Myelofibrosis.

DRUG: KRT-232

DRUG: TL-895

Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, M...

This clinical trial involves individuals who have been diagnosed with Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Chronic Myelomonocytic Leukemia (CMML), or MDS/myeloproliferative neoplasm-unclassifiable (MDS/MPN-unclassifiable) and...

DRUG: Venetoclax

DRUG: Fludarabine

DRUG: Busulfan

DRUG: Venetoclax

DRUG: Azacitidine

DRUG: Decitabine/cedazuridine

Venetoclax and Azacitidine for the Treatment of Relapsed or Refractory High-Risk Myelodysplastic Syn...

This phase I/II trial investigates the side effects and best dose of venetoclax when given together with azacitidine and to see how well it works in treating patients with high-risk myelodysplastic syndrome or chronic myelomonocytic leukemia that has...

DRUG: Azacitidine

DRUG: Venetoclax

Bone Marrow and Kidney Transplant for Patients With Chronic Kidney Disease and Blood Disorders

The main purpose of this study is to examine the outcome of a combined bone marrow and kidney transplant from a partially matched related (haploidentical or "haplo") donor. This is a pilot study, you are being asked to participate because you have a ...

PROCEDURE: Haploidentical Bone Marrow/Kidney

Study of Elenestinib (BLU-263) in Advanced Systemic Mastocytosis (AdvSM) and and Other KIT Altered H...

The goal of this clinical trial is to evaluate elenestinib (BLU-263) in participants with Advanced Systemic Mastocytosis (AdvSM), SM with an associated hematologic neoplasm (SM-AHN), and other hematologic malignancies. The main questions it aims to a...

DRUG: BLU-263

DRUG: Azacitidine

Infusion of Expanded Cord Blood Cells in Addition to Single Cord Blood Transplant in Treating Patien...

This phase II trial studies how well donor umbilical cord blood transplant with ex-vivo expanded cord blood progenitor cells (dilanubicel) works in treating patients with blood cancer. Before the transplant, patients will receive chemotherapy (fludar...

BIOLOGICAL: Dilanubicel

DRUG: Cyclophosphamide

DRUG: Fludarabine

DRUG: Thiotepa

RADIATION: Total-Body Irradiation

PROCEDURE: Umbilical Cord Blood Transplantation

OTHER: Laboratory Biomarker Analysis

PROCEDURE: Biospecimen Collection

PROCEDURE: Bone Marrow Aspirate

PROCEDURE: Bone Marrow Biopsy

PROCEDURE: Multigated Acquisition Scan

PROCEDURE: Electrocardiography

PROCEDURE: Computed Tomography

ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML

This research study is evaluating a drug called ABL001 taken in combination with dasatinib (Sprycel®) and prednisone (a steroid) as a possible treatment for B-cell Acute Lymphoblastic Leukemia that is BCR-ABL positive (BCR-ABL+ B-ALL) or Chronic Myel...

DRUG: ABL001

DRUG: Dasatinib

DRUG: Prednisone

DRUG: Blinatumomab

Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders

This is a single-arm study to investigate 1-year treatment related mortality (TRM) in patients with life threatening non-malignant and malignant hematologic disorders who do not have a matched related donor for allogeneic transplantation.

DRUG: Clofarabine

DRUG: Fludarabine

DRUG: Busulfan

DRUG: Cyclosporine-A

DRUG: Mycophenolate Mofetil

BIOLOGICAL: Cord Blood Graft

(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis

This is an open-label, two-part Phase 2 study investigating CGT9486 for the treatment of patients with Advanced Systemic Mastocytosis (AdvSM), including patients with Aggressive SM (ASM), SM with Associated Hematologic Neoplasm (SM-AHN), and Mast Cel...

DRUG: bezuclastinib

Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously E...

This is a Phase 2, multicenter, open-label study to provide continued supply of parsaclisib as monotherapy or in combination therapy with itacitinib, ruxolitinib, or ibrutinib to participants from Incyte-sponsored studies of parsaclisib.

DRUG: Parsaclisib

DRUG: parsaclisib + itacitinib

DRUG: parsaclisib + ruxolitinib

DRUG: parsaclisib + ibrutinib

Leading in MPNs Beyond Ruxolitinib in Combo With T-Regs

To assess the safety and tolerability of CK0804 as add-on therapy in participants with myelofibrosis, with suboptimal response to ruxolitinib

DRUG: CK0804

Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignan...

This phase I trial studies the safety of transplantation with a haploidentical donor peripheral blood stem cell graft depleted of TCRαβ+ cells and CD19+ cells in conjunction with the immunomodulating drug, Zoledronate, given in the post-transplant pe...

PROCEDURE: TCRαβ+/CD19+ depleted Haploidentical HSCT

DRUG: Zoledronate

A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelst...

The purpose of the study is to identify the recommended Part 2 dose (R2PD) of imetelstat in combination with ruxolitinib in participants with myelofibrosis (MF) in Part 1, and to evaluate the safety and clinical activity of the R2PD of imetelstat in ...

DRUG: Imetelstat

DRUG: Ruxolitinib

Seclidemstat and Azacitidine for the Treatment of Myelodysplastic Syndrome or Chronic Myelomonocytic...

This phase I/II trial identifies the best dose of seclidemstat when given together with azacitidine in treating patients with myelodysplastic syndrome or chronic myelomonocytic leukemia. Seclidemstat may stop the growth of cancer cells by blocking so...

DRUG: Azacitidine

DRUG: Seclidemstat

Haploidentical Hematopoietic Cell Transplantation Using TCR Alpha/Beta and CD19 Depletion

Patients with medical conditions requiring allogeneic hematopoietic cell transplantation (allo-HCT) are at risk of developing a condition called graft versus host disease (GvHD) which carries a high morbidity and mortality. This is a phase I/II study...

DEVICE: CliniMACS

Personalized NK Cell Therapy in CBT

This phase II clinical trial studies how well personalized natural killer (NK) cell therapy works after chemotherapy and umbilical cord blood transplant in treating patients with myelodysplastic syndrome, leukemia, lymphoma or multiple myeloma. This ...

BIOLOGICAL: Allogeneic Natural Killer Cell Line NK-92

BIOLOGICAL: Anti-Thymocyte Globulin

DRUG: Busulfan

DRUG: Clofarabine

DRUG: Cyclophosphamide

DRUG: Fludarabine Phosphate

OTHER: Laboratory Biomarker Analysis

DRUG: Melphalan

BIOLOGICAL: Rituximab

RADIATION: Total-Body Irradiation

PROCEDURE: Umbilical Cord Blood Transplantation

Improving Cognitive Function in Older Adults Undergoing Stem Cell Transplant

Cancer and treatment-related cognitive changes hinder resumption of normal routine and roles and worsen quality of life. Older adults undergoing hematopoietic cell transplantation (HCT) are at high-risk for cognitive impairment. Physical activity imp...

BEHAVIORAL: CHAMPS-II adapted to adults 60+ years in HCT setting

CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelody...

This phase II trial investigates how well CPX-351 and ivosidenib work in treating patients with acute myeloid leukemia or high-risk myelodysplastic syndrome that has IDH1 mutation. The safety of this drug combination will also be studied. IDH1 is a t...

DRUG: Ivosidenib

DRUG: Liposome-encapsulated Daunorubicin-Cytarabine

Allogeneic Hematopoietic Cell Transplantation With Pegylated Interferon Alfa-2a for Primary and Seco...

This is a single site, open-label, dose de-escalation, Phase 1 study of pegylated interferon alfa-2a administered after alloHCT in subjects with primary or secondary myelofibrosis. Part 1 of the study will assess the rate of dose-limiting toxicities ...

DRUG: Pegylated interferon alpha2a

Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leuke...

The aim of this study is to support development of asciminib in the pediatric population (1 to \<18 years) previously treated with one or more TKIs. Full extrapolation of the efficacy of asciminib from adult to pediatric patients will be conducted. F...

DRUG: Asciminib Pediatric formulation group

DRUG: Asciminib Adult formulation group

A Study to Evaluate INCA033989 Administered in Participants With Myeloproliferative Neoplasms

This study is being conducted to evaluate the safety, tolerability, dose-limiting toxicity (DLT) and determine the maximum tolerated dose (MTD) and/or recommended dose(s) for expansion (RDE) of INCA033989 administered in participants with myeloprolif...

DRUG: INCA033989

A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants W...

This is a study evaluating the safety and efficacy of bomedemstat (MK-3543) compared with the best available therapy (BAT) in participants with essential thrombocythemia (ET) who have an inadequate response to or are intolerant of hydroxyurea. The p...

DRUG: Bomedemstat

DRUG: Anagrelide

DRUG: Busulfan

DRUG: Interferon alfa/pegylated interferon alfa

DRUG: Ruxolitinib

Azacitidine and Quizartinib for the Treatment of Myelodysplastic Syndrome or Myelodysplastic/Myelopr...

This phase I/II trial studies the side effects and best dose of quizartinib when given with azacitidine and to see how well they work in treating patients with myelodysplastic syndrome or myelodysplastic/myeloproliferative neoplasm with FLT3 or CBL m...

DRUG: Azacitidine

DRUG: Quizartinib

A Phase I Study of Decitabine, Lisaftoclax, and Olverembatinib in Patients With Advanced Chronic Mye...

To find the recommended doses of lisaftoclax and olverembatinib that can be given in combination with decitabine to participants with advanced CML and Ph+ AML.

DRUG: Decitabine

DRUG: Listaftoclax

DRUG: Olverembatinib

KRT-232 and TKI Study in Chronic Myeloid Leukemia

This study evaluates KRT-232, a novel oral small molecule inhibitor of MDM2, for the treatment of patients with Ph+ Chronic Myeloid Leukemia (CML) who have relapsed or are refractory or intolerant to a Tyrosine Kinase Inhibitor (TKI). This study is ...

DRUG: KRT-232

DRUG: Dasatinib

DRUG: Nilotinib

Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acu...

This phase II MyeloMATCH treatment trial tests whether the standard approach of cytarabine and daunorubicin in comparison to the following experimental regimens works to shrink cancer in patients with high risk acute myeloid leukemia (AML): 1) daunor...

DRUG: Azacitidine

PROCEDURE: Biospecimen Collection

PROCEDURE: Bone Marrow Aspiration

DRUG: Cytarabine

DRUG: Daunorubicin Hydrochloride

PROCEDURE: Echocardiography

DRUG: Liposome-encapsulated Daunorubicin-Cytarabine

PROCEDURE: Multigated Acquisition Scan

DRUG: Venetoclax

Chimeric Antigen Receptor T Cell Therapy Redirected to CD4 (CD4CAR)as a Second Line Treatment for Ch...

This study is designed as a single arm open label traditional Phase I, 3+3, study of CD4-directed chimeric antigen receptor engineered T-cells (CD4CAR) in patients with relapsed or refractory CMML. Specifically, the study will evaluate the safety and...

BIOLOGICAL: CD4CAR

Phase II Study Assessing Efficacy and Safety of Asciminib in Patients With Newly Diagnosed Chronic M...

To learn if asciminib can help to control CML. The safety and effects of this drug will also be studied.

DRUG: Asciminib

Study of Canakinumab in Patients With Myelofibrosis

This is an open label, multicenter, phase 2 trial of Canakinumab in patients with primary myelofibrosis (PMF), post essential thrombocythemia/polycythemia vera related MF (Post ET/PV MF). Eligible patients will receive Canakinumab administered as a s...

DRUG: Canakinumab

Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patient...

This phase II trial studies how well giving an umbilical cord blood transplant together with cyclophosphamide, fludarabine, and total-body irradiation (TBI) works in treating patients with hematologic diseases. Giving chemotherapy, such as cyclophosp...

PROCEDURE: Biospecimen Collection

PROCEDURE: Bone Marrow Aspirate

DRUG: Cyclophosphamide

DRUG: Cyclosporine

PROCEDURE: Diagnostic Imaging

PROCEDURE: Echocardiography

DRUG: Fludarabine Phosphate

PROCEDURE: Multigated Acquisition Scan

DRUG: Mycophenolate Mofetil

OTHER: Survey Administration

DRUG: Thiotepa

RADIATION: Total-Body Irradiation

PROCEDURE: Umbilical Cord Blood Transplantation

A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malign...

This study will evaluate the safety, tolerability, and efficacy of engineered donor grafts ("OrcaGraft"/"Orca-Q") in participants undergoing myeloablative allogeneic hematopoietic cell transplant transplantation for hematologic malignancies.

BIOLOGICAL: OrcaGraft (Orca-Q)

Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia,...

This phase II trial studies how well cladribine, idarubicin, cytarabine, and venetoclax work in patients with acute myeloid leukemia, high-risk myelodysplastic syndrome, or blastic phase chronic myeloid leukemia. Drugs used in chemotherapy, such as c...

DRUG: Cladribine

DRUG: Cytarabine

DRUG: Gilteritinib

DRUG: Idarubicin

OTHER: Laboratory Biomarker Analysis

DRUG: Midostaurin

DRUG: Venetoclax

Olutasidenib for the Treatment of Patients With IDH1 Mutated AML, MDS or CMML After Donor Hematopoie...

This phase I trial tests the safety, side effects, and effectiveness of olutasidenib in preventing the return of disease (relapse) in patients who have undergone donor (allogeneic) hematopoietic cell transplant for acute myeloid leukemia (AML), myelo...

PROCEDURE: Biospecimen Collection

DRUG: Olutasidenib

Study of KRT-232 or TL-895 in Janus Associated Kinase Inhibitor Treatment-Naïve Myelofibrosis

This study evaluates either KRT-232 or TL-895 in treatment naïve patients with myelofibrosis (MF) The study will be conducted in 2 stages. Stage 1 will evaluate safety, tolerability, and efficacy of either KRT-232 (Arm 1) or TL-895 (Arm 2) in treatm...

DRUG: KRT-232

DRUG: TL-895

Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chron...

This phase II trial studies the effect of ascorbic acid and combination chemotherapy in treating patients with lymphoma that has come back (recurrent) or does not respond to therapy (refractory), clonal cytopenia of undetermined significance and chro...

DIETARY_SUPPLEMENT: Ascorbic Acid

DRUG: Carboplatin

DRUG: Cisplatin

DRUG: Cytarabine

DRUG: Dexamethasone

DRUG: Etoposide

DRUG: Gemcitabine Hydrochloride

DRUG: Ifosfamide

OTHER: Laboratory Biomarker Analysis

DRUG: Oxaliplatin

OTHER: Placebo Administration

OTHER: Questionnaire Administration

BIOLOGICAL: Rituximab

DRUG: Decitabine

PROCEDURE: Biospecimen Collection

PROCEDURE: Core Biopsy

PROCEDURE: Bone Marrow Aspiration

PROCEDURE: Bone Marrow Biopsy

PROCEDURE: Echocardiography

PROCEDURE: Positron Emission Tomography

PROCEDURE: Magnetic Resonance Imaging

PROCEDURE: Central Venous Cannula Insertion

PROCEDURE: Portacath Placement

PROCEDURE: Computed Tomography

Pembrolizumab and Dasatinib, Imatinib Mesylate, or Nilotinib in Treating Patients With Chronic Myelo...

This phase II trial studies how well pembrolizumab and dasatinib, imatinib mesylate, or nilotinib work in treating patients with chronic myeloid leukemia and persistent detection of minimal residual disease, defined as the levels of a gene product ca...

DRUG: Dasatinib

DRUG: Imatinib Mesylate

OTHER: Laboratory Biomarker Analysis

DRUG: Nilotinib

BIOLOGICAL: Pembrolizumab

Protocol Number: HJKC3-0003. Treatment Free Remission After Combination Therapy With Asciminib (ABL0...

This is a single arm phase II study that will enroll a minimum of 47 subjects with a maximum of 51. All patients will have a confirmed diagnosis of chronic phase chronic myeloid Leukemia and must have previously attempted to discontinue Tyrosine Kina...

DRUG: Asciminib 40 MG

DRUG: Asciminib 40 MG Twice Daily

DRUG: Asciminib 80 MG daily

DRUG: Imatinib

DRUG: Nilotinib

DRUG: Dasatinib

Study to Assess SLN124 in Patients With Polycythemia Vera

This is a Phase 1/2, multicenter study with an open-label dose escalation followed by a randomized placebo controlled and double-blind phase of SLN124 in adult patients with Polycythemia Vera (PV) to assess the safety, tolerability, efficacy, pharmac...

DRUG: SLN124

DRUG: Placebo

Curcumin to Improve Inflammation and Symptoms in Patients With Clonal Cytopenia of Undetermined Sign...

This phase II trial evaluates how a curcumin supplement (C3 complex/Bioperine) changes the inflammatory response and symptomatology in patients with clonal cytopenia of undetermined significance (CCUS), low risk myelodysplastic syndrome (LR-MDS), and...

PROCEDURE: Biospecimen Collection

PROCEDURE: Bone Marrow Aspiration

PROCEDURE: Bone Marrow Biopsy

DIETARY_SUPPLEMENT: Curcumin/ Demethoxycurcumin/Bisdemethoxycurcumin-containing Supplement

DIETARY_SUPPLEMENT: Piperine Extract (Standardized)

DRUG: Placebo Administration

OTHER: Questionnaire Administration

Combination Chemotherapy (FLAG-Ida) With Pivekimab Sunirine (PVEK [IMGN632]) for the Treatment of Ne...

This phase I trial finds the best dose of PVEK when given together with fludarabine, cytarabine, granulocyte colony-stimulating factor (G-CSF), and idarubicin, (FLAG-Ida) regimen and studies the effectiveness of this combination therapy in treating p...

PROCEDURE: Biospecimen Collection

PROCEDURE: Bone Marrow Aspiration

PROCEDURE: Bone Marrow Biopsy

DRUG: Cytarabine

PROCEDURE: Echocardiography

DRUG: Fludarabine

DRUG: Granulocyte Colony-Stimulating Factor

DRUG: Idarubicin

PROCEDURE: Multigated Acquisition Scan

DRUG: Pivekimab Sunirine

MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies

This is a phase II, open-label, prospective study of T cell receptor alpha/beta depletion (α/β TCD) peripheral blood stem cell (PBSC) transplantation for children and adults with hematological malignancies

DRUG: Fludarabine

DRUG: Busulfan

DRUG: Melphalan

DRUG: Rituximab

DRUG: Levetiracetam

Testing the Effect of Taking Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Ph...

This phase I/II trial studies the best dose of ruxolitinib when given together with CPX-351 and to see how well they work in treating patients with accelerated phase or blast phase myeloproliferative neoplasm. Ruxolitinib may stop the growth of cance...

PROCEDURE: Allogeneic Hematopoietic Stem Cell Transplantation

DRUG: Liposome-encapsulated Daunorubicin-Cytarabine

DRUG: Ruxolitinib

Hyperbaric Oxygen Therapy and Allogeneic Peripheral Blood Stem Cell (PBSC) Transplant

The purpose of this study is to determine if hyperbaric oxygen therapy is safe in the setting of stem cell transplantation. This study will also determine if hyperbaric oxygen therapy improves engraftment, graft versus host disease, neutrophil count,...

DRUG: Hyperbaric oxygen

INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Ane...

This Phase 1/2, open-label, dose-finding study is intended to evaluate the safety and tolerability, PK, PD, and efficacy of INCB000928 administered as monotherapy or in combination with ruxolitinib in participants with MF who are transfusion-dependen...

DRUG: INCB000928

DRUG: ruxolitinib

Study of Tagraxofusp for Post-Transplant Maintenance for Patients With CD 123+ AML, MF and CMML (HSC...

In this study, tagraxofusp (Tag) is given to patients with CD 123+ myelofibrosis (MF), chronic myelomonocytic leukemia (CMML), and acute myeloid leukemia (AML) after allogeneic stem cell transplant (HCT) to help prevent relapse. Patients will receive...

DRUG: Tagraxofusp

Study of TL-895 in Subjects With Myelofibrosis or Indolent Systemic Mastocytosis

This study evaluates TL-895, a potent, orally-available and highly selective irreversible tyrosine kinase inhibitor for the treatment of Myelofibrosis (Cohorts 1-3) or Indolent Systemic Mastocytosis (Cohort 5). Participants must be diagnosed with Mye...

DRUG: TL-895

DRUG: Placebo

Ponatinib Hydrochloride as Second Line Therapy in Treating Patients With Chronic Myeloid Leukemia in...

This phase II trial studies how well ponatinib hydrochloride works as second line therapy in treating patients with chronic myeloid leukemia in chronic phase that has not responded to initial treatment (first line) with imatinib mesylate, dasatinib, ...

OTHER: Laboratory Biomarker Analysis

DRUG: Ponatinib Hydrochloride

OTHER: Quality-of-Life Assessment

A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thr...

The main purpose of this study with corresponding optional expansion is to evaluate the efficacy of selinexor in JAKi-naïve participants with myelofibrosis (MF) and moderate thrombocytopenia based on spleen volume reduction (SVR). Additional efficacy...

DRUG: Selinexor 60 mg

DRUG: Selinexor 40 mg

DRUG: Ruxolitinib

DRUG: Pacritinib

DRUG: Momelotinib

Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Dis...

This is a treatment guideline for an unrelated umbilical cord blood transplant (UCBT) using a myeloablative preparative regimen for the treatment of hematological diseases, including, but not limited to acute leukemias. The myeloablative preparative ...

DRUG: Fludarabine

DRUG: Cyclophosphamide

RADIATION: Total Body Irradiation

DRUG: Cyclosporine A

DRUG: Mycophenylate mofetil

BIOLOGICAL: Umbilical cord blood

Alpha/Beta T Cell and CD19+ B Cell Depletion in Allogeneic Stem Cell Transplantation in Patients Wit...

This study will assess the safety, efficacy, and feasibility of ⍺/β CD3+ T-cell and CD19+ B-cell depletion in allogeneic stem cell transplantation in patients with acute lymphocytic leukemia (ALL), acute myeloid leukemia (AML), juvenile myelomonocyti...

DEVICE: Miltenyi CliniMACS Prodigy ® system

Selumetinib and Azacitidine in High Risk Chronic Blood Cancers

This is a phase I, open-label, dose-escalation study to determine the MTD of selumetinib when combined with the standard dose of azacitidine. Treatment will begin within 28 days of screening procedures. Treatment will continue indefinitely, provided ...

DRUG: Azacitidine

DRUG: Selumetinib

A Study to Assess Safety, Tolerability and Preliminary Efficacy of Bexmarilimab in Combination With ...

This is a study to assess the safety of increasing dose levels of bexmarilimab when combined with standard of care (SoC) in patients with myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML) or acute myeloid leukemia (AML); Phase ...

DRUG: Bexmarilimab

DRUG: Azacitidine

DRUG: Venetoclax

Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis

This is a global, multicenter Phase 1/3 study to evaluate the efficacy and safety of selinexor plus ruxolitinib in JAK inhibitor (JAKi) treatment-naïve myelofibrosis (MF) participants. The study will be conducted in two phases: Phase 1 (open-label) a...

DRUG: Selinexor

OTHER: Placebo

DRUG: Ruxolitinib

A Safety and Tolerability Study of Jaktinib

This research study is studying a drug called Jaktinib as a possible treatment for Myelofibrosis.

DRUG: Jaktinib Hydrochloride Tablet

CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chron...

This phase I trial studies best dose and side effects of liposome-encapsulated daunorubicin-cytarabine (CPX-351) and how well it works in treating patients with high risk myelodysplastic syndrome or chronic myelomonocytic leukemia that has come back ...

DRUG: Liposome-encapsulated Daunorubicin-Cytarabine

Peritransplant Ruxolitinib for Patients With Primary and Secondary Myelofibrosis

This phase II trial studies how well administering ruxolitinib before, during, and after allogeneic hematopoietic stem cell transplantation works in preventing graft versus host disease and improving transplant outcomes in patients with primary and s...

PROCEDURE: Allogeneic Hematopoietic Stem Cell Transplantation

DRUG: Busulfan

DRUG: Cyclophosphamide

DRUG: Fludarabine

DRUG: Melphalan

DRUG: Methotrexate

DRUG: Mycophenolate Mofetil

DRUG: Ruxolitinib

DRUG: Tacrolimus

RADIATION: Total-Body Irradiation

PROCEDURE: Computed Tomography

PROCEDURE: Echocardiography

PROCEDURE: Bone Marrow Aspiration and Biopsy

PROCEDURE: Magnetic Resonance Imaging

PROCEDURE: Ultrasound Imaging

Ruxolitinib in Treating Patients With Hypereosinophilic Syndrome or Primary Eosinophilic Disorders

This phase II trial studies how well ruxolitinib works in treating patients with hypereosinophilic syndrome or primary eosinophilic disorders.

DRUG: Ruxolitinib

A Study of ASTX030 (Cedazuridine in Combination With Azacitidine) in MDS, CMML, or AML

Study ASTX030-01 is designed to move efficiently from Phase 1 to Phase 3. Phase 1 consists of an open-label Dose Escalation Stage (Stage A) using multiple cohorts at escalating dose levels of oral cedazuridine and azacitidine (only one study drug wil...

DRUG: Azacitidine

DRUG: ASTX030 (cedazuridine + azacitidine)

DRUG: Cedazuridine

A Study of BGB-11417 in Participants With Myeloid Malignancies

The study will determine the safety, tolerability, recommended Phase 2 dose (RP2D) and preliminary efficacy of BGB-11417 as monotherapy and in combination with azacitidine in participants with acute myeloid leukemia (AML) and myelodysplastic syndrome...

DRUG: BGB-11417

DRUG: Azacitidine

DRUG: Posaconazole

DRUG: BGB-11417

NTX-301 in MDS/AML

NTX-301 is a DNMT1 inhibitor. The drug is an oral drug with preclinical data that has shown preclinical anti-leukemic efficacy. This is the first clinical trial using NTX-301 in patients with myeloid malignancies.

DRUG: NTX-301

Safety And Efficacy Of TKI Cessation For CML Patients With Stable Molecular Response In A Real World...

This is a single-arm, phase II study to evaluate safety and efficacy of tyrosine kinase inhibitor (TKI) cessation for chronic myeloid leukemia (CML) patients with stable molecular response in a real world population.

OTHER: Imatinib Mesylate, Dasatinib, Nilotinib or Bosutinib Withdrawal

DRUG: Imatinib Mesylate, Dasatinib, Nilotinib or Bosutinib Re-initiation

An Optimal Dose Finding Study of N-Acetylcysteine in Patients With Myeloproliferative Neoplasms

This is a phase I/II study evaluating the optimal dose of N-acetylcysteine (N-AC) in patients with myeloproliferative neoplasms (MPN).

DRUG: N-Acetylcysteine

Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Ha...

This clinical trial is evaluating whether addition of navtemadlin to ruxolitinib treatment will provide more clinical benefit than ruxolitinib alone for patients with Myelofibrosis who have a suboptimal response to ruxolitinib treatment alone. Subje...

DRUG: Navtemadlin

DRUG: Navtemadlin placebo

DRUG: Ruxolitinib

Liposome-encapsulated Daunorubicin-Cytarabine and Gemtuzumab Ozogamicin in Treating Patients With Re...

This phase II trial studies the side effects and how well liposome-encapsulated daunorubicin-cytarabine and gemtuzumab ozogamicin work in treating patients with acute myeloid leukemia that has come back (relapsed) or that does not respond to treatmen...

DRUG: Gemtuzumab Ozogamicin

DRUG: Liposome-encapsulated Daunorubicin-Cytarabine

OTHER: Quality-of-Life Assessment

CD45RA Depleted Peripheral Stem Cell Addback for Viral or Fungal Infections Post TCRαβ/CD19 Depleted...

The major morbidities of allogeneic hematopoietic stem cell transplant with non-human leukocyte antigen (HLA) matched siblings are graft vs host disease (GVHD) and life threatening infections. T depletion of the donor hematopoietic stem cell graft is...

DEVICE: CliniMACS Cell Processing System for TCRαβ + T Cell and CD45RA Depleted Peripheral Stem Cell Addback

A Study of CFI-400945 With or Without Azacitidine in Patients With AML, MDS or CMML

The purpose of this study is to test the safety of an investigational drug called CFI-400945 alone and in combination with azacitidine.

DRUG: CFI-400945

DRUG: Azacitidine

A Safety, Tolerability and Efficacy Study of NC525 in Subjects With Advanced Myeloid Neoplasms

This is an open-label, non-randomized, Phase 1 study to determine the safety and tolerability of NC525. This study will also assess the clinical benefit in subjects with advanced myeloid neoplasms.

DRUG: NC525

Expanded/Activated Gamma Delta T-cell Infusion Following Hematopoietic Stem Cell Transplantation and...

Gamma delta T-cells are part of the innate immune system with the ability to recognize malignant cells and kill them. This study uses gamma delta T-cells to maximize the anti-tumor response and minimize graft versus host disease (GVHD) in leukemic an...

DRUG: EAGD T-cell infusion (Phase I)

DRUG: EAGD T-cell infusion (Expansion)

A Phase II Study of Cladribine and Low Dose Cytarabine in Combination With Venetoclax, Alternating W...

To learn if the combination of cladribine, cytarabine, venetoclax, and azacitidine can help to control higher-risk myelodysplastic syndrome (MDS) with excess blasts and/or higher-risk chronic myelomonocytic leukemia (CMML).

DRUG: Cladribine

DRUG: Cytarabine

DRUG: Venetoclax

DRUG: Azacitidine

Combination Chemotherapy, Total Body Irradiation, and Donor Blood Stem Cell Transplant in Treating P...

This pilot phase I trial studies the side effects of combination chemotherapy, total body irradiation, and donor blood stem cell transplant in treating patients with secondary myelofibrosis. Drugs used in chemotherapy work in different ways to stop t...

PROCEDURE: Allogeneic Hematopoietic Stem Cell Transplantation

DRUG: Cyclophosphamide

DRUG: Fludarabine

BIOLOGICAL: Glycosylated Recombinant Human G-CSF AVI-014

OTHER: Laboratory Biomarker Analysis

DRUG: Melphalan

DRUG: Mycophenolate Mofetil

DRUG: Tacrolimus

RADIATION: Total-Body Irradiation

Asciminib as Initial Therapy for Patients With Chronic Myeloid Leukemia in Chronic Phase

This study is a multicenter Phase 2, non-randomized, open-label single-group frontline study administering asciminib in patients with newly diagnosed Chronic Myeloid Leukemia-Chronic Phase (CML-CP). The aim of this study is to evaluate the efficacy a...

DRUG: Asciminib

DRUG: Ascimininb + Nilotinib

DRUG: Asciminib + Imatinib

DRUG: Asciminib + Dasatinib

MCW Alpha/Beta T-Cell and B-Cell Depletion With Targeted ATG Dosing

This is a single arm pilot study for patients with hematologic malignancies receiving unrelated or haploidentical related mobilized peripheral stem cells (PSCs) using the CliniMACS system for alpha/beta T cell depletion plus CD19+ B cell depletion wi...

DEVICE: Magnetic-Activated Cell Sorter (CliniMACS, Miltenyi)

ASTX727 and Dasatinib for the Treatment of Newly Diagnosed Philadelphia Chromosome or BCR-ABL Positi...

This phase II trial studies the effect of ASTX727 and dasatinib in treating patients with newly diagnosed Philadelphia chromosome or BCR-ABL positive chronic myeloid leukemia in chronic phase. Philadelphia chromosome positive and BCR-ABL positive are...

DRUG: Dasatinib

DRUG: Decitabine and Cedazuridine

Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodyspla...

This phase I trial studies the side effects and best dose of edetate calcium disodium or succimer in treating patients with acute myeloid leukemia or myelodysplastic syndrome undergoing chemotherapy. Edetate calcium disodium or succimer may help to l...

DRUG: Edetate Calcium Disodium

DIETARY_SUPPLEMENT: Multivitamin

DRUG: Succimer

A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adul...

The study is designed to compare the tolerability of asciminib versus nilotinib for the treatment of newly diagnosed, previously untreated patients with Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP).

DRUG: Asciminib

DRUG: Nilotinib

Tagraxofusp and Decitabine for the Treatment of Chronic Myelomonocytic Leukemia

This phase I/II trial studies the side effects, best dose, and effect of tagraxofusp and decitabine in treating patients with chronic myelomonocytic leukemia. Tagraxofusp consists of human interleukin 3 (IL3) linked to a toxic agent called DT388. IL3...

DRUG: Decitabine

BIOLOGICAL: Tagraxofusp-erzs

A Phase I/II Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomon...

This clinical trial will test the safety and efficacy of combining trametinib and azacitidine in patients with juvenile myelomonocytic leukemia (JMML). Newly diagnosed lower-risk JMML patients will receive trametinib and azacitidine. High-risk JMML p...

DRUG: Trametinib

DRUG: Azacitidine

DRUG: Fludarabine

DRUG: Cytarabine

Venetoclax in Combination With ASTX727 for the Treatment of Chronic Myelomonocytic Leukemia and Othe...

This phase II trial tests whether decitabine and cedazuridine (ASTX727) in combination with venetoclax work better than ASTX727 alone at decreasing symptoms of bone marrow cancer in patients with chronic myelomonocytic leukemia (CMML), myelodysplasti...

PROCEDURE: Biospecimen Collection

PROCEDURE: Bone Marrow Biopsy

DRUG: Decitabine and Cedazuridine

DRUG: Venetoclax

Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematol...

This phase Ib/II trial studies the side effects and best dose of venetoclax and how well it works when given together with ivosidenib with or without azacitidine, in treating patients with IDH1-mutated hematologic malignancies. Venetoclax and ivoside...

DRUG: Azacitidine

DRUG: Ivosidenib

DRUG: Venetoclax

CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infect...

This phase II clinical trial tests how well the cytomegalovirus-modified vaccinica Ankara (CMV-MVA) Triplex vaccine given to human leukocyte antigens (HLA) matched related stem cell donors works to prevent cytomegalovirus (CMV) infection in patients ...

PROCEDURE: Allogeneic Hematopoietic Stem Cell Transplantation

PROCEDURE: Biospecimen Collection

DRUG: Granulocyte Colony-Stimulating Factor

DRUG: Hematopoietic Cell Transplantation Conditioning Regimen

BIOLOGICAL: Multi-peptide CMV-Modified Vaccinia Ankara Vaccine

PROCEDURE: Pheresis

DRUG: Placebo Administration

DRUG: Stem Cell Mobilization Therapy

Pacritinib in CMML

This is a phase 1/2 trial of pacritinib in combination with azacitidine in patients with Chronic Myelomonocytic Leukemia (CMML). Patients will be newly diagnosed or previously treated but could not have received a prior JAK inhibitor. Patients who ha...

DRUG: Pacritinib

DRUG: Azacitidine

Reduced Intensity Haploidentical Transplantation for the Treatment of Primary or Secondary Myelofibr...

This initial cohort of this phase II trial studied the outcomes of using a JAK inhibitor prior to reduced intensity haploidentical (Haplo) transplantation for the treatment of primary or secondary myelofibrosis (MF). The primary risk of using Haplo H...

DRUG: Cyclophosphamide

DRUG: JAK Inhibitor

DRUG: Fludarabine

BIOLOGICAL: Recombinant Granulocyte Colony-Stimulating Factor

DRUG: Melphalan

DRUG: Mycophenolate Mofetil

PROCEDURE: Peripheral Blood Stem Cell Transplantation

DRUG: Tacrolimus

RADIATION: Total-Body Irradiation

PROCEDURE: Computed Tomography

PROCEDURE: Magnetic Resonance Imaging

PROCEDURE: Bone Marrow Biopsy

PROCEDURE: Bone Marrow Aspiration

PROCEDURE: Biospecimen Collection

PROCEDURE: Echocardiography

PROCEDURE: Multigated Acquisition Scan

Inqovi Maintenance Therapy in Myeloid Neoplasms

This research is being done to see if the drug Inqov is effective in reducing the chance of myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML) relapsing after standard of care stem cell transplant. * This research study involve...

DRUG: Inqovi

Study on Efficacy and Safety of Givinostat Versus Hydroxyurea in Patients With Polycythemia Vera

The goal of this clinical trial is to compare the efficacy and safety of givinostat to hydroxyurea in Jak2V617F-positive high risk polycythemia vera patients.

DRUG: Givinostat

DRUG: Hydroxyurea

Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MP...

This is a Phase 1, multi-center, open-label study with a dose-escalation phase (Phase 1a) and a cohort expansion phase (Phase 1b), to evaluate the safety, tolerability, and PK profile of LP-118 under a once daily oral dosing schedule in up to 100 sub...

DRUG: LP-118

Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromos...

This phase II trial studies how well blinatumomab, methotrexate, cytarabine, and ponatinib work in treating patients with Philadelphia chromosome (Ph)-positive, or BCR-ABL positive, or acute lymphoblastic leukemia that has come back or does not respo...

BIOLOGICAL: Blinatumomab

DRUG: Cytarabine

DRUG: Methotrexate

DRUG: Ponatinib

A Phase II, Open-Label, Study of Subcutaneous Canakinumab, an Anti-IL-1β Human Monoclonal Antibody, ...

This phase II trial studies how well canakinumab works for the treatment of low- or intermediate-risk myelodysplastic syndrome or chronic myelomonocytic leukemia. Canakinumab is a monoclonal antibody that may interfere with the ability of cancer cell...

BIOLOGICAL: Canakinumab

Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Stud...

This study is intended to collect safety data from participants who completed the parent protocols but are still benefiting from study treatment. The study population consists of participants who tolerate study treatment of the parent studies. Collec...

DRUG: decitabine

DRUG: spartalizumab

DRUG: sabatolimab

DRUG: azacitidine

DRUG: venetoclax

DRUG: INQOVI (oral decitabine)

KRT-232 Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relap...

This study evaluates KRT-232, a novel oral small molecule inhibitor of MDM2, for the treatment of patients with myelofibrosis (MF) who no longer benefit from treatment with a JAK inhibitor. Inhibition of MDM2 is a novel mechanism of action in MF. Th...

DRUG: KRT-232

DRUG: Best Available Therapy (BAT)

A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants...

This is a Phase 1 dose-escalation study of PRT2527, a potent and highly selective cyclin-dependent kinase (CDK) 9 inhibitor, in participants with select relapsed or refractory (R/R) hematologic malignancies. The purpose of this study is to evaluate t...

DRUG: PRT2527

DRUG: Zanubrutinib

DRUG: Venetoclax

Cobimetinib in Newly Diagnosed or HMA-treated CMML Patients With RAS Pathway Mutations

This is an open-label, nonrandomized phase 2 trial to assess the efficacy of cobimetinib in RAS pathway activated CMML. All eligible patients will be treated daily with cobimetinib in 28-day cycles. Cobimetinib will be administered for three weeks f...

DRUG: Cobimetinib

Asciminib Roll-over Study

This is a long term safety study for patients who have completed a Novartis sponsored asciminib study and are judged by the investigator to benefit from continued treatment

DRUG: Asciminib single agent

DRUG: Imatinib

DRUG: Nilotinib

DRUG: Bosutinib

DRUG: Dasatinib

Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL

A multi-center, open-label, randomized, phase Ib study to evaluate the pharmacokinetics (PK) of HQP1351 and to determine the recommended phase 2 dose (RP2D) of HQP1351 in subjects with CML chronic phase (CP), accelerated phase (AP), or blast phase (B...

DRUG: Ascentage Pharma HQP1351 bioavailable inhibitor

DRUG: Blinatumomab

Off-the-shelf NK Cells + SCT for Myeloid Malignancies

The goal of this clinical research study is to learn about the safety and effectiveness of giving KDS-1001 in combination with a standard stem cell transplant to patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), or chronic m...

DRUG: Cyclophosphamide

DRUG: Mesna

DRUG: Filgrastim

DRUG: Melphalan

DRUG: Fludarabine phosphate

DRUG: Tacrolimus

DRUG: Mycophenolate mofetil

DRUG: Total Body Irradiation One Dose

Reparixin in Patients With Myelofibrosis Myeloproliferative Neoplasms Research Consortium (MPN-RC 12...

This is an open label, phase II study to assess the efficacy, safety, and tolerability of Reparixin in patients with DIPSS intermediate-2, or high-risk primary myelofibrosis (PMF), post essential thrombocythemia/polycythemia vera related MF (Post ET/...

DRUG: reparixin

Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Be...

One of the ways that cancer grows and spreads is by avoiding the immune system.NK cells are immune cells that kill cancer cells, but are often malfunctioning in people with colorectal cancer and blood cancers. A safe way to give people with colorecta...

DRUG: Vactosertib

DRUG: Fludarabine Phosphate

DRUG: Cyclophosphamide

DRUG: IL-2

DRUG: Natural Killer Cells

A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (AC...

A Phase 3b, open-label, single-arm, rollover study to evaluate the long-term safety of luspatercept, to the following participants: * Participants receiving luspatercept on a parent protocol at the time of their transition to the rollover study, who...

DRUG: Luspatercept

A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies

CP-MGD024-01 is a Phase 1, open-label, multi-center study of MGD024 as a single agent in patients with select blood cancers that have not responded to treatment with standard therapies or who have relapsed after treatment. The study is designed to de...

DRUG: MGD024

A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017)

The primary purpose of the study is to transition participants into an extension study to collect long-term safety and efficacy data. The study will include participants who are safely tolerating bomedemstat, receiving clinical benefit from its use i...

DRUG: Bomedemstat

CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for th...

This phase I trial studies the best dose of total body irradiation when given with cladribine, cytarabine, filgrastim, and mitoxantrone (CLAG-M) or idarubicin, fludarabine, cytarabine and filgrastim (FLAG-Ida) chemotherapy reduced-intensity condition...

DRUG: Cladribine

DRUG: Cyclophosphamide

DRUG: Cyclosporine

DRUG: Cytarabine

BIOLOGICAL: Filgrastim

PROCEDURE: Hematopoietic Cell Transplantation

DRUG: Mitoxantrone

DRUG: Mycophenolate Mofetil

DRUG: Mycophenolate Sodium

RADIATION: Total-Body Irradiation

DRUG: Idarubicin

DRUG: Fludarabine

DRUG: Cytarabine

PROCEDURE: Multigated Acquisition Scan

PROCEDURE: Echocardiography

PROCEDURE: X-Ray Imaging

PROCEDURE: Bone Marrow Biopsy

PROCEDURE: Bone Marrow Aspiration

Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders

This is a Phase II study of allogeneic hematopoietic stem cell transplant (HCT) using a myeloablative preparative regimen (of either total body irradiation (TBI); or, fludarabine/busulfan for patients unable to receive further radiation). followed by...

BIOLOGICAL: HSCT with TBI Regimen

BIOLOGICAL: HSCT with Non-TBI Regimen

Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspet...

The main purpose of this study is to identify a safe and potentially effective dose of tuspetinib to be used in future studies in study participants diagnosed with acute myeloid leukemia (AML), myelodysplastic syndromes with increased blasts grade 2 ...

DRUG: Tuspetinib

DRUG: Venetoclax Oral Tablet

DRUG: Azacitidine for Intravenous Infusion

Maintenance Fedratinib to Prevent Post-Transplant Relapse in Myeloproliferative Neoplasms

The purpose of the study is to evaluate the effectiveness and safety of fedratinib as maintenance therapy in participants with myeloproliferative neoplasms (MPNs) after allogeneic hematopoietic cell transplant (HCT).

DRUG: Fedratinib Pill

Venetoclax in Combination With ASTX727 for the Treatment of Treatment-Naive High-Risk Myelodysplasti...

This phase I/II trial studies the side effects and best dose of venetoclax in combination with cedazuridine and decitabine (ASTX727) in treating patients with high risk myelodysplastic syndrome or chronic myelomonocytic leukemia who have not received...

DRUG: Decitabine and Cedazuridine

DRUG: Venetoclax

A Study of Dual-SIgnaling Protein 107 (DSP107) for Patients With Hematological Malignancies

This study will be divided into two parts, Parts A and B and will enroll patients with relapsed/refractory AML or MDS/chronic myelomonocytic leukemia (CMML) patients who have failed up to 2 prior therapeutic regimens. Part A is a dose escalation stu...

BIOLOGICAL: DSP107

DRUG: Azacitidine

DRUG: Venetoclax

An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined With Rux...

This is a phase 1b/2 study of KRT-232 combined with ruxolitinib in subjects with MF who have a suboptimal response after at least 18 weeks of treatment with ruxolitinib. The primary objective of the study is to determine a recommended phase 2 dose (R...

DRUG: KRT-232

DRUG: Ruxolitinib

A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasm...

The purpose of this study is to characterize safety and to determine the Recommended Phase 2 Dose (RP2D\[s\]) and optimal dosing schedule(s) of JNJ-88549968, in part 1 (Dose Escalation); to characterize the safety of JNJ- 88549968 at RP2D(s), in part...

DRUG: JNJ-88549968

FHD-286 as Monotherapy or Combination Therapy in Subjects With Advanced Hematologic Malignancies

This Phase 1, multicenter, open-label, dose escalation study is designed to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinical activity of FHD-286 administered orally as monotherapy or combination ...

DRUG: FHD-286

DRUG: Low Dose Cytarabine

DRUG: Decitabine

A Study to Evaluate Sapablursen (Formerly ISIS 702843, IONIS-TMPRSS6-LRx) in Patients With Polycythe...

The main purpose of this study is to evaluate the efficacy of sapablursen in reducing the frequency of phlebotomy and in improving quality of life assessments in participants with polycythemia vera.

DRUG: sapablursen

Need Help?

Legal Info

Charity Navigator

HealthTree Foundation is a qualified 501(c)(3) tax-exempt organization.

Tax ID 45-5354811

Get the latest thought leadership on your Myeloproliferative Neoplasm delivered straight to your inbox

Education

Community

Cure Hub

Get Involved

About us

Need Help?

Legal Info